LIR Life Sciences Initiates Phase 2 Peptide Design with Neuland Laboratories

LIR Life Sciences Corp. has announced the commencement of Project Phase 2 peptide design activities in collaboration with Neuland Laboratories Limited. This phase focuses on the design and optimization of next-generation cell-penetrating peptides, aimed at advancing LIR's transdermal delivery platform.

Following the successful synthesis of peptides in Phase 1, Phase 2 involves systematic structure-activity relationship analysis to develop third-generation peptide candidates. The goal is to enhance transdermal transport activity and improve synthetic and formulation flexibility.

This partnership aims to refine peptide structures and set synthesis targets for future evaluation, with results expected to guide subsequent testing programs. CEO Edward Mills emphasized the importance of this phase in understanding structure-activity relationships, which are crucial for molecular design and manufacturability.